Extreme hypercalcemia in a kidney transplant recipient

Post-transplant hypercalcemia remains a poorly understood complication that may impact graft and patient outcomes. Prior research has shown that elevated serum calcium levels can lead to renal dysfunction and systemic toxicity. However, the mechanisms behind extreme hypercalcemia in transplant recipients are not fully clarified. No prior work had resolved how to effectively manage severe cases unresponsive to standard therapies. This gap motivated further investigation into treatment strategies and underlying pathologies. Current knowledge lacks detailed case reports on hemodialysis use for extreme hypercalcemia. The role of PTLD in this context remains underexplored. This paper contributes a rare clinical example with a unique therapeutic approach. The findings may help refine emergency protocols for transplant recipients.

This case report aimed to document an unusual presentation of extreme hypercalcemia in a kidney transplant recipient. The goal was to evaluate the effectiveness of various treatment modalities in a life-threatening scenario. The specific problem addressed was the management of refractory hypercalcemia with multi-drug resistance. The motivation arose from the lack of established protocols for such extreme cases. The study focused on the sequence of interventions and their outcomes. It also aimed to highlight the diagnostic process for PTLD in transplant patients. The authors sought to emphasize the role of hemodialysis in emergency settings. The findings may inform future clinical decision-making in similar cases.

The study involved a single 66-year-old male kidney transplant recipient with extreme hypercalcemia. Initial treatment included isotonic saline, furosemide, and methylprednisolone. When ineffective, calcitonin and ibandronate were added. Hemodialysis with low-calcium dialysate was initiated after treatment resistance. Diagnostic investigations included PET/CT imaging and bone marrow biopsy. The diagnostic approach focused on identifying the underlying cause of hypercalcemia. Treatment adjustments were made based on clinical response and laboratory data. The case was managed in an intensive care unit setting.

The patient presented with serum calcium of 22.1 mg/dL, the highest value reported in this context. Initial treatments failed to reduce calcium levels effectively. Hemodialysis with low-calcium dialysate achieved normalization within three days. PET/CT showed FDG uptake in bones and spleen, suggesting neoplastic activity. Bone marrow biopsy confirmed CD20+ B-cell infiltration consistent with PTLD. Immunosuppressive therapy was modified with tacrolimus replaced by everolimus. R-CHOP regimen was initiated to treat PTLD. Despite interventions, the patient succumbed to septic shock on day 10.

The authors emphasize the importance of hemodialysis as an emergent treatment for extreme hypercalcemia in transplant recipients. They highlight the diagnostic value of PET/CT and bone marrow biopsy in identifying PTLD. The study shows that standard therapies may be insufficient in refractory cases. The findings suggest that early dialytic intervention may be life-saving. The authors note that PTLD can have a rapidly progressive and fatal course. They caution that transplant recipients with extreme hypercalcemia require aggressive management. The study underscores the need for multidisciplinary approaches in such cases. The authors conclude that hemodialysis should be considered in treatment-resistant hypercalcemia.